PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO pep… Read more
PepGen Ltd (PEPG) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.107x
Based on the latest financial reports, PepGen Ltd (PEPG) has a cash flow conversion efficiency ratio of -0.107x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.85 Million) by net assets ($147.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PepGen Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how PepGen Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PepGen Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PepGen Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KARAT PACKAGING DL -001
F:0WJ
|
N/A |
|
Ensari Deri Gida Sanayi ve Ticaret AS
IS:ENSRI
|
0.094x |
|
FAWER Automotive Parts Ltd Co
SHE:200030
|
0.029x |
|
Jiangsu Dongzhu Landscape Co
SHG:603359
|
0.011x |
|
Doright Co.Ltd.
SHE:300950
|
-0.007x |
|
Xuancheng Valin Precision Technology Co Ltd
SHG:603356
|
0.112x |
|
Gujarat Ambuja Exports Limited
NSE:GAEL
|
0.042x |
|
Kailong High Technology Co. Ltd.
SHE:300912
|
N/A |
Annual Cash Flow Conversion Efficiency for PepGen Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of PepGen Ltd from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $147.44 Million | $-81.64 Million | -0.554x | +20.27% |
| 2024-12-31 | $118.62 Million | $-82.37 Million | -0.694x | -9.12% |
| 2023-12-31 | $108.42 Million | $-69.00 Million | -0.636x | -92.89% |
| 2022-12-31 | $179.63 Million | $-59.27 Million | -0.330x | -94.31% |
| 2021-12-31 | $133.09 Million | $-22.60 Million | -0.170x | -0.46% |
| 2020-12-31 | $9.77 Million | $-1.65 Million | -0.169x | +26.15% |
| 2019-12-31 | $3.87 Million | $-885.00K | -0.229x | -- |